Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (191-200 of 275) with videos related to

Pageof 28
Sort By:
JCO Oncology Practice|August 9, 2023
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World DataJeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopRobert Pirker, Felix J F Herth, Keith M Kerr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
Epidermal growth factor receptor inhibition in lung cancer: status 2012Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III TrialRobert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2012
Identifying and targeting ROS1 gene fusions in non-small cell lung cancerKurtis D Davies, Anh T Le, Mariana F Theodoro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
Pageof 28

Showing results (191-200 of 275) with videos related to

Sort By:
Pageof 28
JCO Oncology Practice|August 9, 2023
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World DataJeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.
JTO Clinical and Research Reports|November 24, 2025
Crizotinib in Patients With <i>ROS1</i>-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS TrialLorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopRobert Pirker, Felix J F Herth, Keith M Kerr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
Epidermal growth factor receptor inhibition in lung cancer: status 2012Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III TrialRobert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2012
Identifying and targeting ROS1 gene fusions in non-small cell lung cancerKurtis D Davies, Anh T Le, Mariana F Theodoro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
Pageof 28